EPCAM and neoplasm: To determine whether treatment with CD3xEpCAM was sufficient to impact tumor growth in vivo, C57BL/6 mice were implanted with B16F10/EpCAM tumor cells and then treated with either CD3xEpCAM or CD3xnull control bispecific antibody as described.